Potentiating the antitumor effects of chemotherapy with the selective PI3K inhibitor XL147

被引：0
|
作者：
Foster, Paul G. [1 ]
机构：
[1] Exelixis Inc, San Francisco, CA USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2007年 / 6卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3592S / 3592S
页数：1
相关论文
共 50 条
  • [41] The antitumor effects of PI3K beta inhibitors in PTEN negative prostate cancer are enhanced by inhibition of reactivated PI3K alpha signaling
    Schwartz, Sarit
    Carver, Brett S.
    Wongvipat, John
    Rodrik-Outmezguine, Vanessa
    Stanchina, Elisa D.
    Trigwell, Cath
    Barry, Simon
    Baselga, Jose
    Chandarlapaty, Sarat
    Scher, Howard I.
    Sawyers, Charles L.
    Rosen, Neal
    CANCER RESEARCH, 2014, 74 (19)
  • [42] HM5016699, a novel and selective PI3K/mTOR dual inhibitor
    Ren, Yongxin
    Zhang, Weihan
    Cui, Yumin
    Guo, Mingchuan
    Long, Jingwen
    Sai, Yang
    Wang, Jian
    Yan, James
    Li, Jia
    Qing, Weiguo
    Su, Weiguo
    CANCER RESEARCH, 2011, 71
  • [43] SELETALISIB, A NOVEL SELECTIVE PI3KΔ INHIBITOR WITH THERAPEUTIC POTENTIAL IN INFLAMMATION AND AUTOIMMUNITY
    Payne, A.
    Juarez, M.
    Johnston, G. I.
    Helmer, E.
    Thomson, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 287 - 288
  • [44] Discovery and antiplatelet activity of a selective PI3Kβ inhibitor (MIPS-9922)
    Zheng, Zhaohua
    Pinson, Jo-Anne
    Mountford, Simon J.
    Orive, Stephanie
    Schoenwaelder, Simone M.
    Shackleford, David
    Powell, Andrew
    Nelson, Erin M.
    Hamilton, Justin R.
    Jackson, Shaun P.
    Jennings, Ian G.
    Thompson, Philip E.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2016, 122 : 339 - 351
  • [45] Development of a practical synthesis to PI3K α-selective inhibitor GDC-0326
    Koenig, Stefan G.
    Green, Keena L.
    Muller, Barbara
    Sowell, C. Gregory
    Askin, David
    Gosselin, Francis
    TETRAHEDRON, 2021, 79
  • [46] MEN1611, a novel α-selective PI3K inhibitor in solid tumors
    Merlino, Giuseppe
    Fiascarelli, Alessio
    Bigioni, Mario
    Bressan, Alessandro
    Irrissuto, Clelia
    Pellacani, Andrea
    Scaltriti, Maurizio
    Binaschi, Monica
    CANCER RESEARCH, 2018, 78 (13)
  • [47] In vitro profiling of the potent and selective PI3K inhibitor AEZS-126
    Seipelt, Irene
    Gerlach, Matthias
    Blumenstein, Lars
    Mueller, Gilbert
    Teifel, Michael
    Polymeropoulos, Emmanuel
    Guenther, Eckhard
    CANCER RESEARCH, 2009, 69
  • [48] Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway
    Yu, Peiwen
    Laird, Douglas
    Du, Xiangnan
    Wu, Jianming
    Won, Kwang-Ai
    Yamaguchi, Kyoko
    Hsu, Pin Pin
    Qian, Fawn
    Jaeger, Christopher T.
    Zhang, Wentao
    Buhr, Chris A.
    Shen, Paula
    Abulafia, Wendy
    Chen, Jason
    Young, Jenny
    Plonowski, Arthur
    Yakes, F. Michael
    Chu, Felix
    Lee, Michelle
    Bentzien, Frauke
    Lam, Sanh Tan
    Dale, Stephanie
    Matthews, David J.
    Lamb, Peter
    Foster, Paul
    MOLECULAR CANCER THERAPEUTICS, 2014, 13 (05) : 1078 - 1091
  • [49] Design, synthesis and antitumor effects of novel benzimidazole derivatives as PI3K inhibitors
    Wu, Wenping
    Li, Sisi
    Chen, Junjie
    Duo, Tena
    Ma, Cheng
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2023, 95
  • [50] Synergistic Effects of Targeted PI3K Signaling Inhibition and Chemotherapy in Liposarcoma
    Guo, Shang
    Lopez-Marquez, Hector
    Fan, Kenneth C.
    Choy, Edwin
    Cote, Gregory
    Harmon, David
    Nielsen, G. Petur
    Yang, Cao
    Zhang, Changqing
    Mankin, Henry
    Hornicek, Francis J.
    Borger, Darrell R.
    Duan, Zhenfeng
    PLOS ONE, 2014, 9 (04):
12345